These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 33070220)
1. Oncogenic pathways activated by pro-inflammatory cytokines promote mutant p53 stability: clue for novel anticancer therapies. D'Orazi G; Cordani M; Cirone M Cell Mol Life Sci; 2021 Mar; 78(5):1853-1860. PubMed ID: 33070220 [TBL] [Abstract][Full Text] [Related]
2. p53-R273H Sustains ROS, Pro-Inflammatory Cytokine Release and mTOR Activation While Reducing Autophagy, Mitophagy and UCP2 Expression, Effects Prevented by wtp53. Romeo MA; Gilardini Montani MS; Benedetti R; Arena A; D'Orazi G; Cirone M Biomolecules; 2021 Feb; 11(3):. PubMed ID: 33668399 [No Abstract] [Full Text] [Related]
3. Recent Advances on Mutant p53: Unveiling Novel Oncogenic Roles, Degradation Pathways, and Therapeutic Interventions. Cordani M; Garufi A; Benedetti R; Tafani M; Aventaggiato M; D'Orazi G; Cirone M Biomolecules; 2024 May; 14(6):. PubMed ID: 38927053 [TBL] [Abstract][Full Text] [Related]
4. Interplay between Endoplasmic Reticulum (ER) Stress and Autophagy Induces Mutant p53H273 Degradation. Garufi A; Federici G; Gilardini Montani MS; Crispini A; Cirone M; D'Orazi G Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32138264 [TBL] [Abstract][Full Text] [Related]
5. A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status. Garufi A; Baldari S; Pettinari R; Gilardini Montani MS; D'Orazi V; Pistritto G; Crispini A; Giorno E; Toietta G; Marchetti F; Cirone M; D'Orazi G J Exp Clin Cancer Res; 2020 Jun; 39(1):122. PubMed ID: 32605658 [TBL] [Abstract][Full Text] [Related]
6. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells. Cai J; Xia J; Zou J; Wang Q; Ma Q; Sun R; Liao H; Xu L; Wang D; Guo X FEBS Open Bio; 2020 Apr; 10(4):535-545. PubMed ID: 32027103 [TBL] [Abstract][Full Text] [Related]
7. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis. Yue X; Wu F; Li Y; Liu J; Boateng M; Mandava K; Zhang C; Feng Z; Gao J; Hu W Cell Cycle; 2020 Jun; 19(11):1338-1351. PubMed ID: 32275841 [TBL] [Abstract][Full Text] [Related]
8. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins. Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706 [TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of suppressor of cytokine signaling 3 on inflammatory cytokine expression and migration and proliferation of IL-6/IFN-γ-induced vascular smooth muscle cells. Xiang S; Dong NG; Liu JP; Wang Y; Shi JW; Wei ZJ; Hu XJ; Gong L J Huazhong Univ Sci Technolog Med Sci; 2013 Oct; 33(5):615-622. PubMed ID: 24142708 [TBL] [Abstract][Full Text] [Related]
10. Fucoxanthin from microalgae Phaeodactylum tricornutum inhibits pro-inflammatory cytokines by regulating both NF-κB and NLRP3 inflammasome activation. Lee AH; Shin HY; Park JH; Koo SY; Kim SM; Yang SH Sci Rep; 2021 Jan; 11(1):543. PubMed ID: 33436909 [TBL] [Abstract][Full Text] [Related]
11. Immunological Approaches Towards Cancer and Inflammation: A Cross Talk. Qu X; Tang Y; Hua S Front Immunol; 2018; 9():563. PubMed ID: 29662489 [TBL] [Abstract][Full Text] [Related]
12. Mutant p53 proteins alter cancer cell secretome and tumour microenvironment: Involvement in cancer invasion and metastasis. Cordani M; Pacchiana R; Butera G; D'Orazi G; Scarpa A; Donadelli M Cancer Lett; 2016 Jul; 376(2):303-9. PubMed ID: 27045472 [TBL] [Abstract][Full Text] [Related]
13. Gain-of-function mutant p53 in cancer progression and therapy. Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796 [TBL] [Abstract][Full Text] [Related]
14. Regulation of p53 stability as a therapeutic strategy for cancer. Xu Z; Wu W; Yan H; Hu Y; He Q; Luo P Biochem Pharmacol; 2021 Mar; 185():114407. PubMed ID: 33421376 [TBL] [Abstract][Full Text] [Related]
15. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Chen X; Zhang T; Su W; Dou Z; Zhao D; Jin X; Lei H; Wang J; Xie X; Cheng B; Li Q; Zhang H; Di C Cell Death Dis; 2022 Nov; 13(11):974. PubMed ID: 36400749 [TBL] [Abstract][Full Text] [Related]
16. Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP. Di Minin G; Bellazzo A; Dal Ferro M; Chiaruttini G; Nuzzo S; Bicciato S; Piazza S; Rami D; Bulla R; Sommaggio R; Rosato A; Del Sal G; Collavin L Mol Cell; 2014 Dec; 56(5):617-29. PubMed ID: 25454946 [TBL] [Abstract][Full Text] [Related]